Omalizumab in therapy of severe bronchial asthma
Nowadays, use of anti-IgE antibodies (omalizumab) represents the only existing phenotype-specific therapy of severe IgE-mediated allergic bronchial asthma (BA). Here, a mechanism of action and results of clinical studies on safety and efficacy of omalizumab in patients with BA are analyzed. Indications for administration of omalizumab, its importance in modern step therapy of BA as well as future perspectives are examined.